These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35905311)

  • 1. Cases in the management of prostate cancer: the addition of darolutamide to androgen deprivation therapy and docetaxel in a 55-year-old man with metastatic hormone-sensitive prostate cancer.
    Crawford ED
    Clin Adv Hematol Oncol; 2022 Jul; 20 Suppl 14(7):1-8. PubMed ID: 35905311
    [No Abstract]   [Full Text] [Related]  

  • 2. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
    Smith MR; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford ED; Kopyltsov E; Park CH; Alekseev B; Montesa-Pino Á; Ye D; Parnis F; Cruz F; Tammela TLJ; Suzuki H; Utriainen T; Fu C; Uemura M; Méndez-Vidal MJ; Maughan BL; Joensuu H; Thiele S; Li R; Kuss I; Tombal B;
    N Engl J Med; 2022 Mar; 386(12):1132-1142. PubMed ID: 35179323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.
    Smith MR; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford D; Manarite J; Muslin D; Farrington T; Tombal B
    Future Oncol; 2022 Jul; 18(21):2585-2597. PubMed ID: 35656777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K; Smith MR; Tombal B
    Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S; Lang JM; Jarrard DF
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
    Fizazi K; Foulon S; Carles J; Roubaud G; McDermott R; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Gravis G; Calabro F; Berdah JF; Hasbini A; Silva M; Thiery-Vuillemin A; Latorzeff I; Mourey L; Laguerre B; Abadie-Lacourtoisie S; Martin E; El Kouri C; Escande A; Rosello A; Magne N; Schlurmann F; Priou F; Chand-Fouche ME; Freixa SV; Jamaluddin M; Rieger I; Bossi A;
    Lancet; 2022 Apr; 399(10336):1695-1707. PubMed ID: 35405085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis.
    Guo Z; Lu X; Yang F; Qin L; Yang N; Wu J; Wang H
    Eur J Med Res; 2022 Aug; 27(1):148. PubMed ID: 35953852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
    Narita S; Kimura T; Hatakeyama S; Hata K; Yanagisawa T; Maita S; Chiba S; Sato H; Kashima S; Koizumi A; Yamamoto R; Takayama K; Okane K; Ishida T; Horikawa Y; Kumazawa T; Shimoda J; Suzuki T; Ohyama C; Egawa S; Nomura K; Habuchi T
    World J Urol; 2022 May; 40(5):1135-1141. PubMed ID: 35218371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
    Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
    Zhang F; Lu YP
    Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.
    Smith MR; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Le Berre MA; Mohamed AF; Odom D; Bartsch J; Snapir A; Sarapohja T; Fizazi K
    Eur J Cancer; 2021 Sep; 154():138-146. PubMed ID: 34273811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent trends in the management of advanced prostate cancer.
    Ritch C; Cookson M
    F1000Res; 2018; 7():. PubMed ID: 30345007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy combined with androgen-deprivation therapy in high-volume metastatic hormone sensitive prostate cancer: a short-term efficacy and safety analysis].
    Xu PH; Shen YJ; Xiao WJ; Lin GW; Qin XJ; Zhu Y; Dai B; Ye DW
    Zhonghua Wai Ke Za Zhi; 2019 Jun; 57(6):418-421. PubMed ID: 31142065
    [No Abstract]   [Full Text] [Related]  

  • 14. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
    Shiota M; Eto M
    Int J Urol; 2016 May; 23(5):360-9. PubMed ID: 27062039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal Therapy for Prostate Cancer.
    Desai K; McManus JM; Sharifi N
    Endocr Rev; 2021 May; 42(3):354-373. PubMed ID: 33480983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
    Iguchi T; Kimura G; Fukasawa S; Suzuki H; Uemura H; Nishimura K; Matsumoto H; Yokomizo A; Armstrong AJ; Rosbrook B; Sugg J; Baron B; Chen L; Kunieda F; Stenzl A
    Int J Urol; 2021 Jul; 28(7):765-773. PubMed ID: 33955599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cases in the management of nonmetastatic castration-resistant prostate cancer: darolutamide as the first androgen receptor inhibitor in a fit, older man.
    Lowentritt BH
    Clin Adv Hematol Oncol; 2022 Jan; 20 Suppl 1(1):1-8. PubMed ID: 35343943
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of hormone-naïve metastatic prostate cancer.
    Hamilou Z; Saad F; Fizazi K
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):334-338. PubMed ID: 30015691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and efficacy of early docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in a rural health care setting.
    Nieder C; Stanisavljevic L; Dalhaug A; Haukland E
    Scand J Urol; 2022 Apr; 56(2):114-118. PubMed ID: 35174779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer.
    Byeon S; Kim H; Jeon HG; Seo SI; Jeon SS; Lee HM; Lee SI; Park SH
    BMC Cancer; 2021 Nov; 21(1):1281. PubMed ID: 34839812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.